Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;87(6):1336-1342.
doi: 10.1016/j.jaad.2022.08.028. Epub 2022 Aug 23.

Artificial intelligence in the detection of skin cancer

Eric J Beltrami  1 , Alistair C Brown  2 , Paul J M Salmon  2 , David J Leffell  3 , Justin M Ko  4 , Jane M Grant-Kels  5
Affiliations
Review

Artificial intelligence in the detection of skin cancer

Eric J Beltrami et al. J Am Acad Dermatol. 2022 Dec.

Abstract

Recent advances in artificial intelligence (AI) in dermatology have demonstrated the potential to improve the accuracy of skin cancer detection. These capabilities may augment current diagnostic processes and improve the approach to the management of skin cancer. To explain this technology, we discuss fundamental terminology, potential benefits, and limitations of AI, and commercial applications relevant to dermatologists. A clear understanding of the technology may help to reduce physician concerns about AI and promote its use in the clinical setting. Ultimately, the development and validation of AI technologies, their approval by regulatory agencies, and widespread adoption by dermatologists and other clinicians may enhance patient care. Technology-augmented detection of skin cancer has the potential to improve quality of life, reduce health care costs by reducing unnecessary procedures, and promote greater access to high-quality skin assessment. Dermatologists play a critical role in the responsible development and deployment of AI capabilities applied to skin cancer.

Keywords: artificial intelligence; clinical practice; diagnosis; health care dollars; machine learning; neural networks; skin cancer; technology.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Drs Salmon and Leffell are the medical advisors and stockholders for DermaSensor, Inc. Dr Ko is a Chair of the AAD Committee on Augmented Intelligence and a medical advisor for SkinAnalytics. Dr Grant-Kels is a medical advisor, and stockholder for DermaSensor, Inc and VerraDermics, Inc. Drs Beltrami and Brown have no conflicts of interest to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles